Denali Therapeutics Inc.DNLINASDAQ
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank59
5Y CAGR-89.4%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
-89.4%/yr
Long-term compound
Percentile
P59
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 8.16% |
| Q3 2025 | -42.50% |
| Q2 2025 | 42.73% |
| Q1 2025 | -57.04% |
| Q4 2024 | -41.56% |
| Q3 2024 | 35.17% |
| Q2 2024 | 19.71% |
| Q1 2024 | -15.17% |
| Q4 2023 | -12.93% |
| Q3 2023 | 22.80% |
| Q2 2023 | -92.46% |
| Q1 2023 | 19.08% |
| Q4 2022 | -27.38% |
| Q3 2022 | -32.98% |
| Q2 2022 | 40.51% |
| Q1 2022 | -10.10% |
| Q4 2021 | -58.07% |
| Q3 2021 | 23.58% |
| Q2 2021 | -7.92% |
| Q1 2021 | -109.78% |
| Q4 2020 | 597475.58% |
| Q3 2020 | 100.20% |
| Q2 2020 | 20.43% |
| Q1 2020 | -14.38% |
| Q4 2019 | -56.54% |
| Q3 2019 | 29.51% |
| Q2 2019 | -42.38% |
| Q1 2019 | -132.54% |
| Q4 2018 | 367.60% |
| Q3 2018 | 16.74% |
| Q2 2018 | -224.56% |
| Q1 2018 | 283.12% |
| Q4 2017 | 16.35% |
| Q3 2017 | -24.77% |
| Q2 2017 | 6.59% |
| Q1 2017 | -2.41% |
| Q4 2016 | 13.72% |
| Q3 2016 | -30.17% |
| Q2 2016 | 0.00% |
| Q1 2016 | 0.00% |